Company Encyclopedia
View More
name
Landfar
000504.SZ
Landfar Bio-medicine Co., Ltd operates as a biomedical technology company. The company operates through Biomedicine, and Energy Saving and Environmental Protection segments. The Biomedicine segment engages in the provision of stem cell storage and technical services; stem cell therapy research; medical device procurement and sales, etc. The Energy Saving and Environmental Protection segment is involved in the external energy management contract energy management business; build-transfer business and sales of related products; and sewage treatment business.
1.579 T
000504.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking78/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-2.53%D
    • Profit Margin-4.94%D
    • Gross Margin63.30%A
  • Growth ScoreB
    • Revenue YoY0.82%C
    • Net Profit YoY83.27%A
    • Total Assets YoY41.72%A
    • Net Assets YoY20.40%A
  • Cash ScoreD
    • Cash Flow Margin-2022.74%E
    • OCF YoY0.82%C
  • Operating ScoreD
    • Turnover0.17D
  • Debt ScoreD
    • Gearing Ratio56.93%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ST Landfar plans to acquire 51% equity of Huize Pharmaceutical, which is expected to constitute a significant asset restructuring situation

    Landfar plans to acquire 51% equity of Hunan Huize Pharmaceutical in cash, which is expected to constitute a major asset reorganization. After the transaction, Huize Pharmaceutical will become a subsidiary and be included in the consolidated financial statements. Huize Pharmaceutical focuses on drug research and development as well as clinical evaluation, providing pharmaceutical research, clinical trials, and other services. This acquisition aims to enhance the profitability and risk resistance of the biopharmaceutical sector and improve the company's operational efficiency

    Zhitong·
    SZ
    000504
    +1.22%
    Zhitong·
    SZ
    000504
    +1.22%

    Overview of the lifting of restrictions on the sale of A-shares | July 10

    On July 10th, a total of 4 listed companies had their restricted shares unlocked, with a total market value of approximately 1.973 billion yuan. The specific situation of the restricted share unlocks today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocking Shares NanHua Biological 000504 Additional A Shares Original Shareholder Allocation Listing 18.4492 million TGOOD 300001 Equity Incentive Restricted Circulation 4.5561 million Weike Technology 301196 Pre-issue Shares Restricted Circulation 56.9 million Tiancheng Technology 688603 7.267 million

    Zhitong·
    SZ
    300001
    +1.99%
    SZ
    000504
    +1.22%
    Zhitong·
    SZ
    300001
    +1.99%
    SZ
    000504
    +1.22%

    ST Landfar plans to list the sale of a 52% stake in its subsidiary Nanhua Heping

    ST Landfar announced plans to list the sale of its 52% equity stake in Nanhua Peace Hospital Management (Hunan) Co., Ltd. on the Hunan United Property Rights Exchange. This move aims to adjust and optimize the business structure, with the listing price referencing relevant assessment conclusions and not being lower than the assessed value, taking into account factors such as the transfer of control over the target assets

    Zhitong·
    SZ
    000504
    +1.22%
    Zhitong·
    SZ
    000504
    +1.22%

    The ST sector strengthened, with over 20 stocks hitting the daily limit up

    The ST sector strengthened, with *ST GUANDIAN rising over 6%, and more than 20 stocks including *ST LANGOLD, ST RUIHE, *ST DYRS, and *ST Landfar hitting the daily limit

    Zhitong·
    SZ
    002620
    -4.20%
    SZ
    000504
    +1.22%
    SH
    688287
    +8.48%
    Zhitong·
    SZ
    002620
    -4.20%
    SZ
    000504
    +1.22%
    SH
    688287
    +8.48%

    Landfar Bio-medicine: The company's stock trading may be subject to delisting risk warning

    According to the announcement from Landfar Bio-medicine, the company expects its net profit for the fiscal year 2024 and net profit after deducting non-recurring gains and losses to both be negative, and the operating income after deduction is expected to be below 300 million yuan. According to Article 9.3.1 (1) of the Shenzhen Stock Exchange Stock Listing Rules, after the disclosure of the company's 2024 annual report, the trading of the company's stock may be subject to delisting risk warning (the stock abbreviation will be prefixed with "*ST")

    Zhitong·
    SZ
    000504
    +1.22%
    Zhitong·
    SZ
    000504
    +1.22%
    © 2025 Longbridge｜Disclaimer